Overview

A Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia

Status:
Active, not recruiting
Trial end date:
2020-05-28
Target enrollment:
Participant gender:
Summary
This is a randomized, placebo-controlled, double-blind, crossover study of oral BTD-001 in adults with Idiopathic Hypersomnia.
Phase:
Phase 2
Details
Lead Sponsor:
Balance Therapeutics
Treatments:
Pentylenetetrazole